

Hepatitis C

Please fax responses to: 1-866-668-1214

Drug Utilization Review Team

Form 13-835A must be submitted as a coversheet

For more information on authorization criteria go to:

http://www.hca.wa.gov/billers-providers/programs-and-services/apple-health-medicaid-drug-coverage-criteria

| Patient | | | Date of birth | | ProviderOne client ID | | | | |
|--|---|---------------------|--------------------------------|----------------------|---|---------------------------------|--|--|--|
| Pharmacy name | | Pharmacy NPI | | Telephone number | | Fax number | | | |
| Prescriber | | | Telephone nu | | mber | Fax number | | | |
| Select a Treatment Regimen For Patient | | | | | | | | | |
| SEVERITY OF LIVER DISEASE | Treat as no cirrhosis: | | | | | | | | |
| | Treat as compensated cirrhosis: F4 (never previously decompensated) | | | | | | | | |
| | Treat as decompensated cirrhosis: F4 (any history of decompensation) Has patient been referred/evaluated by a transplant hepatologist? Yes No | | | | | | | | |
| REQUESTED TREATMENT | Mavyret 8 weeks Epclusa 12 weeks Epclusa + RBV 12 weeks | | | | | | | | |
| REGIMEN | Vosevi 12 weeks Vosevi + RBV 12 weeks | | | | | | | | |
| | Other regimen: What medication(s) and duration requested: | | | | | | | | |
| | Reason for selecting a non-preferred regimen: | | | | | | | | |
| | Patient has contraindications to ribavirin. List all contraindications: | | | | | | | | |
| PREVIOUS TREATMENT | No prior HCV treatment | | | | | | | | |
| | Relapse after prior HCV treatment. Sp PEG/RBV Victrelis Incivek Olysio + PEG/RE | Sovaldi Sovaldi | + PEG/RB + RBV - Sovaldi | ☐ Ep ☐ Ze ☐ Vi | arvoni oclusa patier ekira aklinza + So | ☐ Mavyret ☐ Vosevi ovaldi | | | |
| | Previous treatment dates and duration: | | | | | | | | |
| | Was treatment completed? Yes If no, why not? | 🗌 No | | | | | | | |
| | | | | | | | | | |

| 1. List dates of all HCV antibody labs attached: | | | | | | | | | |
|--|--|---|--|------|--|--|--|--|--|
| 2. What is patient's genotype? | List dates of a | List dates of all genotype lab(s) attached: | | | | | | | |
| 3. Current HCV RNA viral load: | List dates of a | List dates of all HCV RNA viral loads attached: | | | | | | | |
| 4. What and when were past transmission risk factors? | | | | | | | | | |
| 5. List dates of all resistance-associated substitution (RAS) tests attached: Does RAS test show Y93 mutation? 	Yes 	No | | | | | | | | | |
| 6. List dates of all Fibrosure, Fibroscan, and imaging attached: | | | | | | | | | |
| 7. Please provide the following for APRI scoring: | | | | | | | | | |
| AST level: Date | taken: | Upper normal: | | | | | | | |
| Platelet count: Date taken: | | | | | | | | | |
| 8. Please provide the following for CPT scoring (v Ascites Absent Encephalopathy None | alues indicated sł Slight Grade 1-2 | nould be when liver | was at worst): date determined: date determined: | | | | | | |
| Albumin level: | Date taken: | | | | | | | | |
| Total bilirubin level: | Date taken: | Date taken: | | | | | | | |
| INR value: | Date taken: | | | | | | | | |
| 9. What is patient's creatinine clearance (CrCl)? or eGFR? | | | | | | | | | |
| 10. Has patient had an organ transplant or is awaiting an organ transplant? If yes, what organ? | | | | | | | | | |
| 11. Does patient have any condition that would prevent long term clinical benefit from HCV treatment? 🗌 Yes 🗌 No | | | | | | | | | |
| If yes, please explain: | | | | | | | | | |
| Has patient been told of the risks and benefits of antiviral therapy, told the importance of adherence to treatment, and evaluated for psychosocial readiness for treatment? Yes | | | | | | | | | |
| If no, please explain: | | | | | | | | | |
| 13. Are you a weekly participant in Project ECHO webinars? 🗌 Yes 🗌 No | | | | | | | | | |
| Please provide the following documentation for your patient: | | | | | | | | | |
| All fibrosis staging resultsAll HCV antibody tests and genotype labsAll HCV RNA viral loads takenNS5A/NS3 resistance/mutation test resultsProject ECHO recommendationAlbumin, total bilirubin, INR, AST, platelet countMost current progress notesTransplant hepatologist evaluation | | | | | | | | | |
| Prescriber signature | Prescriber | specialty | | Date | | | | | |



Requesting Hepatitis C Drug Treatment

Prescribers

Authorization is required for Washington Apple Health clients to receive hepatitis C drug treatment. Please see **FFS Drug Coverage Criteria** at **http://www.hca.wa.gov/billers-providers/programs-and-services/apple-health-medicaid-drug-coverage-criteria** for authorization requirements. To request authorization for your patient:

- Go to FFS Drug Coverage Criteria at http://www.hca.wa.gov/billers-providers/programs-and-services/apple-health-medicaid-drug-coverage-criteria
- Read Washington Apple Health Hepatitis C Clinical Policy. Please familiarize yourself with HCA's requirements for Hepatitis C treatment.
- Fax the pharmacy that will be filling the prescription the completed *Hepatitis C request form (13-830A)* as well as all required supporting documentation as listed on the Hepatitis C request form. Incomplete forms or requests without all necessary supporting documentation will delay review.

Pharmacies

To submit a request for hepatitis C drug treatment:

- Complete the agency's *Pharmacy Information Authorization* (13-835A) form as you would for any other authorization request.
- As supporting documentation to the *Pharmacy Information Authorization* (13-835A):
 - Attach *Hepatitis C request form (13-830A)* completed by the prescriber; and
 - All other required documents as listed on the Hepatitis C request form.
- Fax all documents to HCA at: (866) 668-1214. The *Pharmacy Information Authorization* 13-835A must be the first document in the fax transmission.

Incomplete requests, incorrectly completed forms, or failure to include supporting documentation will result in treatment delays. If a request for authorization is submitted without the required Hepatitis C request form and supporting documents, the Agency will contact the prescriber to request these documents, extending the time to complete the authorization process.

Hepatitis C (13-830A) and Pharmacy Information Authorization (13-835A) form can be found at: http://www.hca.wa.gov/billers-providers/forms-and-publications